康芝藥業(300086.SZ):擬投資建設民族藥製劑樓
格隆匯1月25日丨康芝藥業(300086.SZ)公佈,隨着新的藥品管理法及藥品生產監督管理辦法的實施,中藥與化藥分開生產已是大勢所趨同。根據公司發展戰略,公司將通過生產基地整合,通過藥品上市持有人委託加工等形式形成中藥與化藥相分離,因此公司擬在海口國家高新技術產業開發區藥谷工業園藥谷三路6號海南總廠廠區建設“民族藥製劑樓”。
該項目擬拆除公司海口高新區藥谷廠區東南側單層鋼結構廠房後在此地塊新建一棟民族藥製劑樓,總建築面積54375.84平方米,其中地下1層5028.48平方米,地上10層49347.36平方米,採用框剪結構。
擬建民族藥製劑樓主要生產產品有瀉白散、感冒清熱顆粒、止咳橘紅顆粒、柴黃清熱顆粒、婦科調經顆粒、兒童氫溴酸右美沙芬膜、注射用阿奇黴素、注射用氧氟沙星等產品。
該項目總投資為33791.48萬元,其中,固定資產投資32759.63萬元,鋪底流動資金1031.84萬元。固定資產投資中,建設投資31829.63萬元(含建安工程、二次裝修工程及設備工程等工程費用28883.41萬元,工程建設其他費用1430.53萬元,預備費1515.70萬元),建設期利息930.00萬元。
資金來源為銀行貸款20000萬元,其餘資金為公司自籌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.